The efficacy of lafutidine in patients with chemotherapy-induced peripheral neuropathy treated with a taxane.
Phase 2
- Conditions
- Breast cancer
- Registration Number
- JPRN-UMIN000005338
- Lead Sponsor
- Yokohama City University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1)with severe complications (such as liver failure, renal failure, heart failure) 2)with history of allergy 3)administration of Lafutidine within 2weeks before prior to treatment 4)receiving drugs to influence peripheral neuropathy 5)with peripheral neuropathy for other cause (such as severe edema, diabetes, vitamin B12 deficiency) 6)doctor's decision not to be registered to this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method